Psychedelic-assisted Therapy

Effective factors, relationship building, ethical challenges, and practice in Switzerland

Abstract

Psychedelic-assisted therapy is undergoing a scientifically grounded resurgence. Numerous studies have demonstrated the therapeutic efficacy of substances such as psilocybin, LSD, and MDMA in treating various mental health conditions – particularly treatment-resistant depression, PTSD and anxiety disorders. Switzerland holds a special position in this development: as one of the few countries worldwide, it has allowed regulated access to such therapies through compassionate use and approved individual case applications for years. This article examines the current state of research and clinical application with a focus on Switzerland. It integrates recent findings on the mechanisms of action of psychedelic substances and explores central psychotherapeutic factors such as the therapeutic alliance, mindfulness, integration practices, and the role of non-verbal and body-oriented interventions. Ethical questions, especially around the use of touch, are critically discussed, alongside the importance of supervision, intervision, and professional training. The article draws on empirical and theoretical sources and concludes with recommendations for responsibly incorporating psychedelic-assisted therapy into clinical practice.